02:33 , Dec 8, 2018 |  BioCentury  |  Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
22:35 , Oct 6, 2017 |  BioCentury  |  Finance

Cancer aggregator

MPM Capital launched Cullinan Oncology LLC to aggregate cancer assets that on their own would be too risky to build a company around. The firm believes by amassing up to 10 projects at any given...
19:21 , Oct 6, 2017 |  BC Week In Review  |  Financial News

Cullinan raises $150M in series A

On Oct. 3, Cullinan Oncology LLC (Cambridge, Mass.) raised $150 million in a series A round led by the UBS Oncology Impact Fund -- which is managed by MPM Capital -- and F2 Ventures. MPM...
14:33 , Oct 3, 2017 |  BC Extra  |  Financial News

Cullinan raises $150M series A round

Cullinan Oncology LLC (Cambridge, Mass.) raised $150 million in a series A round led by the UBS Oncology Impact Fund -- which is managed by MPM Capital -- and F2 Ventures. MPM created Cullinan to...
22:32 , Jun 22, 2017 |  BC Innovations  |  Product R&D

Bispecific redirection

With an unusual spinout from a startup and BiTE pioneer Patrick Baeuerle on board, MPM Capital is using his next-generation technology to stake new territory in the field. Through Harpoon Therapeutics Inc. and the recently...
00:53 , Jan 14, 2017 |  BioCentury  |  Finance

Omega’s trans-Atlantic bridge

As Omega Funds has moved its center of gravity from Switzerland to the U.S., it has wanted to keep its access to European deals that could turn into big successes in the U.S. like Micromet...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Boehringer Ingelheim, Amgen deal

Boehringer granted Amgen worldwide rights to develop and commercialize BI 836909 ( AMG 420 ), a compound in Phase I testing to treat relapsed and/or refractory multiple myeloma (MM). BI 836909 is a bispecific T...
07:00 , Sep 1, 2016 |  BC Extra  |  Company News

Amgen licenses Boehringer MM candidate

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted Amgen Inc. (NASDAQ:AMGN) global rights to develop and commercialize multiple myeloma candidate BI 836909 (AMG 420). Financial details were not disclosed. BI 836909, a bispecific T cell engager (BiTE)...